Cargando…

Belatacept for the prophylaxis of organ rejection in kidney transplant patients: an evidence-based review of its place in therapy

BACKGROUND: Belatacept is a novel immunosuppressive therapy designed to improve clinical outcomes associated with kidney transplant recipients while minimizing use of calcineurin inhibitors (CNIs). METHODS: We searched for clinical trials related to administration of belatacept to kidney transplant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hardinger, Karen L, Sunderland, Daniel, Wiederrich, Jennifer A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888760/ https://www.ncbi.nlm.nih.gov/pubmed/27307759 http://dx.doi.org/10.2147/IJNRD.S88816

Ejemplares similares

Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation
por: Zhang, Hengcheng, et al.
Publicado: (2021)

Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation
por: Gupta, Gaurav, et al.
Publicado: (2010)

Time-Limited Therapy with Belatacept in Kidney Transplant Recipients
por: Letellier, Thibault, et al.
Publicado: (2022)

Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
por: Wojciechowski, David, et al.
Publicado: (2012)

Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection
por: Ippoliti, Giovanbattista, et al.
Publicado: (2012)

Belatacept Conversion in Kidney After Liver Transplantation
por: Cristea, Octav, et al.
Publicado: (2021)

CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!”
por: Silva, Marcos V., et al.
Publicado: (2012)

Belatacept and mediastinal histoplasmosis in a kidney transplant patient
por: Trimarchi, Hernán, et al.
Publicado: (2016)

Belatacept in kidney transplant patients with systemic lupus erythematosus
por: Carrión-Barberà, Irene, et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants
por: Kumar, Dhiren, et al.
Publicado: (2017)

Ten Years Experience With Belatacept-Based Immunosuppression After Kidney Transplantation
por: Grannas, Gerrit, et al.
Publicado: (2014)

De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)

Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients
por: El Sakhawi, Karim, et al.
Publicado: (2020)

Belatacept in Kidney Transplantation: What Are the True Benefits? A Systematic Review
por: Lombardi, Yannis, et al.
Publicado: (2022)

Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept
por: Schwarz, Chloë, et al.
Publicado: (2023)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

Belatacept in renal transplantation—quo vadis?
por: Westhoff, Timm H.
Publicado: (2016)

Desensitization and belatacept-based maintenance therapy in pregnancy-sensitized monkeys receiving a kidney transplant
por: Manook, Miriam, et al.
Publicado: (2023)

Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction
por: Snyder, Heather S, et al.
Publicado: (2016)

Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients
por: Gouin, Anna, et al.
Publicado: (2020)

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
por: Tawhari, Ibrahim, et al.
Publicado: (2022)

Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response
por: Terrec, Florian, et al.
Publicado: (2021)

Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection
por: Dalal, Pranav, et al.
Publicado: (2009)

Belatacept Treatment of Recurrent Late-onset T Cell–mediated Rejection/Antibody-mediated Rejection With De Novo Donor-specific Antibodies in a Liver Transplant Patient
por: Klintmalm, Göran B., et al.
Publicado: (2022)

Prevention of acute rejection after rescue with Belatacept by association of low-dose Tacrolimus maintenance in medically complex kidney transplant recipients with early or late graft dysfunction
por: Gallo, Ester, et al.
Publicado: (2020)

Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation
por: de Graav, Gretchen N., et al.
Publicado: (2017)

Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
por: Coscia, Lisa, et al.
Publicado: (2023)

Current Therapies in Kidney Transplant Rejection
por: Alasfar, Sami, et al.
Publicado: (2023)

Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients
por: van der Zwan, Marieke, et al.
Publicado: (2018)

2702. A Case Series of Kidney Transplant Recipients on Belatacept with CMV Infection in a Single Academic Center
por: Feller, Fionna, et al.
Publicado: (2023)

Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate
por: Belliere, Julie, et al.
Publicado: (2014)

Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation
por: Schroder, Paul M., et al.
Publicado: (2017)

Phase I study of single‐dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients
por: Moudgil, Asha, et al.
Publicado: (2019)

Opportunistic Infections and Efficacy Following Conversion to Belatacept-Based Therapy after Kidney Transplantation: A French Multicenter Cohort
por: Bertrand, Dominique, et al.
Publicado: (2020)

Conversion to belatacept after lung transplantation: Report of 10 cases
por: Brugière, Olivier, et al.
Publicado: (2023)

Post-transplant aspergillosis and the role of combined neurosurgical and antifungal therapies under belatacept immunosuppression
por: Kasper, Ekkehard M., et al.
Publicado: (2011)

Response: Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation
por: Baan, Carla C., et al.
Publicado: (2018)

Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity
por: Gupta, Shruti, et al.
Publicado: (2018)

Belatacept associated - cytomegalovirus retinitis in a kidney transplant recipient: a case report and review of the literature
por: Deliège, Pierre-Guillaume, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jo5qrjiv8iejt7dtqpqc1drkua